Skip to main navigation

MoonLake

e: info@moonlaketx.com

About us
Science
Investor relations

Site - Main

About us
Science
Investor relations

e: info@moonlaketx.com

INVESTOR RELATIONS

Press Releases

Year

All News
2023
2022
2021

Sep 6 2023

MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11

Read More +

Aug 10 2023

MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update

Read More +

Jul 25 2023

MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts

Read More +

Jun 28 2023

MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares

Read More +

Jun 26 2023

MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering

Read More +

Jun 25 2023

MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa

Read More +

May 12 2023

MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update

Read More +

May 3 2023

MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply

Read More +

Apr 19 2023

MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today

Read More +

Mar 20 2023

MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update

Read More +

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 24

Site - Investor Tools

Contact Us

MoonLake Immunotherapeutics AG Dorfstrasse 29, 6300 Zug, Schweiz/Switzerland

e: info@moonlaketx.com
media: media@moonlaketx.com
IR: ir@moonlaketx.com

Quick Links

Home
About us
Team
Science
Pipeline

Therapeutic focus
Investor relations
Careers
Privacy policy

© 2023 - MoonLake Immunotherapeutics

Privacy Policy